E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with breast lesions undergoing further examination |
Pazienti in accertamento per lesioni mammarie |
|
E.1.1.1 | Medical condition in easily understood language |
Diagnostic workup for breast lesions |
Esame di approfondimento per lesioni mammarie |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10061021 |
E.1.2 | Term | Breast disorder |
E.1.2 | System Organ Class | 10038604 - Reproductive system and breast disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the role of Contrast-Enhanced Spectral Mammography in the diagnostic workup of breast cancer |
Approfondire il ruolo della mammografia con mezzo di contrasto nella diagnostica del tumore della mammella |
|
E.2.2 | Secondary objectives of the trial |
To evaluate CESM diagnostic performance in suspicious breast lesions |
Analizzare il risultato diagnostico del CESM nella valutazione delle lesioni mammarie sospette |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Woman with suspicious breast lesions from FFDM, US and/or MR imaging and for whom a presurgical evaluation is recommended • The subject must be in sufficient good health to be able to undergo standard of care and CESM examinations |
• Donne con sospette lesione mammarie identificate mediante mammografia, ecografia e/o risonanza magnetica e per le quali è necessaria una valutazione pre – chirugica • La paziente deve essere in buona salute per poter affrontare le valutazioni standard e la CESM |
|
E.4 | Principal exclusion criteria |
• The subject is known to have risks of adverse effects with iodine contrast agents. • The subject is asymptomatic and without suspicious findings from routine imaging. • The subject is participating or has participated (within the prior 30 days) in another clinical |
• La paziente presenta rischi di eventi avversi con mezzi di contrasto contenenti iodio. • La paziente è asintomatico e non presenta immagini sospette nell’ analisi di routine. • La paziente partecipa o ha partecipato (entro i 30 giorni precedenti) ad un'altra sperimentazione clinica |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To evaluate the negative predictive value (NPV) of CESM comparison versus the NPV of the micro-histology or final histology (after surgery) |
Valutare il Valore Predittivo Negative (VPN) del CESM versus il VPN dell’istologia della biopsia o dell’istologia dopo la chirurgia |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
2 months in surgery, 2-3 years in case of follow up |
2 mesi in caso di intervento, 2-3 anni in caso di follow up |
|
E.5.2 | Secondary end point(s) |
To establish CESM diagnostic performance in suspicious breast lesions using histology from VABB as gold standard correlating the definite result (after surgery) with preoperative imaging (accuracy). |
Analizzare il risultato diagnostico del CESM nella valutazione delle lesioni mammarie sospette usando l'istologia mediante VABB come standard di riferimento, correlando il risultato definito (dopo l'intervento chirurgico) con l'imaging preoperatorio (accuratezza). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
2 months in surgery, 2-3 years in case of follow up |
2 mesi in caso di intervento, 2-3 anni in caso di follow up |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |